肝功能障碍对S-1疗法诱导的不良反应的影响:一个回顾性队列研究
Yosuke Ando1, Yuki Shibata2, Takuma Ishihara3
1Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan; ysk-ando@fujita-hu.ac.jp.
In vivo (Athens, Greece)
|February 28, 2024
概括
在接受S-1化疗的患者中,总 bilirubin (T-Bil) 水平升高与血小板数量下降相关. 这表明S-1的使用可能会导致肝功能障碍患者的血小板缩.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 功能障碍通常需要减少S-1剂量.
- 降低二皮里米丁脱酶 (DPD) 活性可能导致5-FU的不良事件.
- 目前的指导方针使用S-1安全性总 bilirubin (T-Bil) ≤1.5x ULN,但与肝功能障碍和剂量减少的联系尚不清楚.
研究的目的:
- 调查T-Bil水平显示的肝功能障碍与S-1剂量减少之间的关系.
- 在接受S-1单疗的患者中,确定与不同T-Bil水平相关的临床结果.
主要方法:
- 对接受S-1单一治疗的883名患者的回顾性分析.
- 患者分为低T-Bil (≤2.25) 和高T-Bil (>2.25) 组.
- 主要结局:血液采样结果的变化;分析的临床结果包括红细胞和PLT计数.
主要成果:
- 分析了883名患者和7,511个治疗实例;7,245名在低T-Bil组,266名在高T-Bil组.
- 在T-Bil组和红细胞计数,PLT计数和T-Bil水平之间发现了显著的相关性.
- 高T-Bil组与低T-Bil组相比,RBC和PLT计数显著下降.
结论:
- 在患有肝功能障碍和T-Bil升高的患者中,S-1的使用可能会导致血小板缩.
- 监测T-Bil水平对于在肝功能障碍患者中管理S-1治疗至关重要.
相关概念视频
Factors Influencing Drug Absorption: Disease States and Pharmacology
513
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
513
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Renal Failure: Dose Adjustments
88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88
Diseases of the Liver and Gallbladder
537
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
537


